Long-Term Results after Treatment of Basal Cell Carcinoma of the Eyelid in Southwestern Finland

2007 ◽  
Vol 17 (4) ◽  
pp. 494-500 ◽  
Author(s):  
V. Paavilainen ◽  
J. Tuominen ◽  
V.V. Aho ◽  
K.M. Saari
Keyword(s):  
Basal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Recurrence Rate ◽  
Basal Cell ◽  
Long Term Results ◽  
White Population ◽  
Common Skin ◽  
The Mean

Purpose Basal cell carcinoma (BCC) is the most common skin cancer of the eyelid, showing an increasing incidence in the white population. The authors studied the clinical characteristics and the treatment results of BCC of the eyelid in southwestern Finland during 1977–1997. Methods The authors reviewed the case records of 191 patients with BCC of the eyelids treated at the Turku University Eye Clinic during 1977–1997. The mean follow-up period after the treatment was 8.6±5.2 years. Results The 191 patients had altogether 194 BCC tumors of the eyelid with the mean diameter of the tumor being smaller than 10 mm in 77.3% of cases. Of the 194 BCC tumors of the eyelid 16.0% showed recurrence, and the recurrence rate of all surgically treated tumors was 13.7%. In this study 61 patients (31.9%) developed other malignancies than the BCC of the eyelid including 28 patients (14.7 %) with carcinoma in other locations than skin. Conclusions Incompletely removed BCCs of the eyelid showed only 18.9% recurrence rate during the follow-up time. On the other hand, BCCs of the eyelid should not be underestimated because of the rather high total recurrence rate. The frequency of 31.9% of other malignancies than BCC of the eyelid is remarkably high and requires special attention from the ophthalmologist taking care of the patient with BCC of the eyelid.

scholarly journals A retrospective comparative study of outcome with surgical excision and repair versus nonsurgical and ablative treatments for basal cell carcinoma

2021 ◽  
Vol 0 ◽  
pp. 1-9
Author(s):  
Soniya Mahajan ◽  
Mani Kalaivani ◽  
Gomathy Sethuraman ◽  
Binod Kumar Khaitan ◽  
Kaushal Kumar Verma ◽  
...  
Keyword(s):  
Basal Cell Carcinoma ◽  
Treatment Failure ◽  
Cell Carcinoma ◽  
Basal Cell ◽  
Surgical Excision ◽  
Significant Difference ◽  
Long Term Follow Up ◽  
The Mean

Background: There are few studies on basal cell carcinoma (BCC) from India. Long-term follow-up is available in only one study and the aesthetic outcome of treatment has not been evaluated in Indian patients. Aims: In this retrospective study on BCC, we compared treatment failure, recurrence rates and aesthetic outcomes on long-term follow-up between surgical excision and repair, and nonsurgical and ablative treatments. Methods: Records of patients with BCC treated in the dermatologic surgery clinic over the past 10 years were analyzed. Patients with histopathologically confirmed BCC who could be contacted were evaluated for recurrence, treatment failure, overall satisfaction and aesthetic outcomes by global aesthetic improvement scale. Results: Out of 98 patients, 72 were contactable. Four patients received both nonsurgical and ablative treatments and surgical excision and repair sequentially and were excluded. The mean age of patients was 57.9 ± 15.8 years (24–90 years) and the male: female ratio was 1.6:1. The most common site involved was the face (72.1%) followed by trunk and scalp, and the most common type of BCC was the pigmented superficial type (33.8%), followed by the pigmented noduloulcerative type (16.2%). There was no significant difference between the groups in the number of high-risk cases. The mean follow-up period was 37.1 ± 31.4 (range, 4–120) months. Fifty one patients were treated with surgical excision and repair, and 17 with nonsurgical and ablative treatments (9-imiquimod, 5-cryotherapy, 4-radiotherapy). Treatment failure was seen in 5 (7.4%) patients, all in the nonsurgical and ablative treatments group (P = 0.0006). Recurrence was seen in 2 (2.9%) patients, both in the surgical excision and repair group (P > 0.05). Mean patient satisfaction was significantly higher with surgical excision and repair, though there was no significant difference in the Global Aesthetic Improvement Scale between the groups. Limitations: The sample size was low. Only telephonic and pictorial assessments were done where the patient could not come for follow-up. Conclusions: Surgical excision and repair was associated with better outcomes than nonsurgical and ablative treatments. Treatment failures and adverse events were high with nonsurgical and ablative treatments. The recurrence rate was low.

scholarly journals Use of Cytology in the Diagnosis of Basal Cell Carcinoma Subtypes

2020 ◽  
Vol 9 (3) ◽  
pp. 612
Author(s):  
Paola Pasquali ◽  
Gonzalo Segurado-Miravalles ◽  
Mar Castillo ◽  
Ángeles Fortuño ◽  
Susana Puig ◽  
...  
Keyword(s):  
Retrospective Study ◽  
Basal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Basal Cell ◽  
Inverse Correlation ◽  
Basal Cells ◽  
White Population ◽  
First Line ◽  
Common Skin ◽  
Cytological Features

Background: Basal cell carcinoma (BCC) is the most common skin cancer in the white population. Nonsurgical treatments are first-line alternatives in superficial BCC (sBCC); therefore, differentiating between sBCC and non-sBCC is of major relevance for the clinician. Scraping cytology possesses several advantages, such as an earlier diagnosis and scarring absence, in comparison to a biopsy. Nevertheless, previous studies reported difficulties in differentiating the different BCC subtypes. The objective of this study was to determine the capability and accuracy of scraping cytology to differentiate between sBCC and non-sBCC. Methods: In this retrospective study, cytological samples of histologically confirmed BCC were examined. Select cytological features were correlated to BCC subtypes (sBCC or non-sBCC). Results: A total of 84 BCC samples were included (29 sBCC; 55 non-sBCC). An inverse correlation between the diagnosis of sBCC and the presence of mucin, dehiscence, and grade of atypia in the basal cells was observed. The presence of medium and large basal cell clusters correlated directly to a sBCC diagnosis. The presence of clear cells is strongly associated with sBCC. Therefore, Conclusion: Scraping cytology is reliable in differentiating sBCC from other BCC subtypes.

Long-term Follow-up of Positive Surgical Margins in Basal Cell Carcinoma of the Face

2015 ◽  
Vol 41 (7) ◽  
pp. 761-767 ◽  
Author(s):  
Aykut Bozan ◽  
Sercan Gode ◽  
Isa Kaya ◽  
Banu Yaman ◽  
Mustafa Uslu ◽  
...  
Keyword(s):  
Basal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Basal Cell ◽  
Surgical Margins ◽  
Positive Surgical Margins ◽  
Long Term Follow Up ◽  
The Face

A new Photodynamic therapy protocol for nodular basal cell carcinoma treatment: effectiveness and long-term follow-up.

2021 ◽  
pp. 102668
Author(s):  
Ana Gabriela Salvio ◽  
Donaldo Botelho Veneziano ◽  
Lilian Tan Moriyama ◽  
Natalia Mayumi Inada ◽  
Clóvis Grecco ◽  
...  
Keyword(s):  
Photodynamic Therapy ◽  
Basal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Basal Cell ◽  
Treatment Effectiveness ◽  
Long Term Follow Up ◽  
Therapy Protocol

Follow-Up of Patients With Complete Remission of Locally Advanced Basal Cell Carcinoma After Vismodegib Discontinuation: A Multicenter French Study of 116 Patients

2019 ◽  
Vol 37 (34) ◽  
pp. 3275-3282 ◽  
Author(s):  
Florian Herms ◽  
Jerome Lambert ◽  
Jean-Jacques Grob ◽  
Luc Haudebourg ◽  
Martine Bagot ◽  
...  
Keyword(s):  
Basal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Basal Cell ◽  
Objective Response Rate ◽  
Response Rate ◽  
Objective Response ◽  
Locally Advanced ◽  
Advanced Basal Cell Carcinoma

PURPOSE Vismodegib is a hedgehog pathway inhibitor indicated for the treatment of locally advanced basal cell carcinoma (laBCC), with an objective response rate of 65%, including a 32% complete response (CR). However, adverse effects often lead to drug discontinuation. The objective of our study was to evaluate long-term responses, predictive factors, and management of relapse after vismodegib discontinuation. METHODS An observational retrospective study was conducted in nine French oncodermatology units. We included patients with laBCC with CR on vismodegib who discontinued treatment between March 2012 and January 2016; we reviewed charts up to June 2016. The primary objective was to evaluate median relapse-free survival (RFS). Secondary objectives were risk factors associated with RFS, relapse, and death and treatment modalities after relapse and their efficacy. RESULTS One hundred sixteen patients with laBCC were included. The median RFS was 18.4 months (95% CI, 13.5 to 24.8 months). The RFS rate at 36 months was 35.4% (95% CI, 22.5% to 47.9%) for the total population and 40.0% (95% CI, 25.7% to 53.7%) for patients without Gorlin syndrome. LaBCC to the limbs and trunk was the only variable independently associated with a higher risk of relapse (hazard ratio, 2.77; 95% CI, 1.23 to 6.22; P = .019). Twenty-seven patients (50%) who experienced relapse during follow-up were retreated with vismodegib, with an objective response in 23 (objective response rate, 85%; CR rate, 37%; partial response rate, 48%) and eligibility for surgery in 24 (42%). CONCLUSION Long-term response after vismodegib discontinuation is frequent. Most patients who experience a relapse still respond to vismodegib rechallenge.

External valvuloplasty in the treatment of greater saphenous vein insufficiency: a five-year follow up

2003 ◽  
Vol 18 (3) ◽  
pp. 137-142 ◽  
Author(s):  
B Geier ◽  
I Voigt ◽  
B Marpe ◽  
T Deska ◽  
S El-Gammal ◽  
...  
Keyword(s):  
Patient Satisfaction ◽  
Recurrence Rate ◽  
Saphenous Vein ◽  
Long Term Results ◽  
The Mean ◽  
External Valvuloplasty ◽  
Saphenofemoral Junction ◽  
Vein Insufficiency

Objective: To present the results of external valvuloplasty of the saphenofemoral junction in selected patients with insufficiency of the greater saphenous vein after a mean follow up of 54 months. Methods: A total of 54 legs were prospectively studied and re-examined a mean of 54 months after the operation. The severity of the patients' symptoms and their satisfaction with the procedure were recorded. Furthermore, the venous refill time, the severity of reflux and the diameter of the greater saphenous vein were recorded preoperatively and again at follow up. Results: In 46 cases (85%) the patients were satisfied with the outcome of the procedure. At follow up, the mean severity of symptoms was significantly lower in every symptom category. The venous refill time was reduced by a mean of 5 seconds and the diameter of the greater saphenous vein was reduced by a mean of 3 mm. Reflux in the saphenofemoral junction despite the valvuloplasty was demonstrated in six legs (11.1%), and reflux in the distal saphenous trunk despite a competent valvuloplasty was seen in 18 cases (33.3%). When reflux was present at the follow-up examination, it affected a significantly shorter segment of the greater saphenous vein than preoperatively. Treatment for recurrent symptoms was necessary in 10 (18.5%) limbs. Conclusions: External valvuloplasty of the saphenofemoral junction offers good results in terms of patient satisfaction, relief of symptoms and recurrence rate. With long-term results still pending, this vein-sparing operation might be an alternative to stripping in selected patients.

Ocular preservation with neoadjuvant vismodegib in patients with locally advanced periocular basal cell carcinoma

2018 ◽  
Vol 103 (6) ◽  
pp. 775-780 ◽  
Author(s):  
Oded Sagiv ◽  
Priyadharsini Nagarajan ◽  
Renata Ferrarotto ◽  
Thomas J Kandl ◽  
Sudip D Thakar ◽  
...  
Keyword(s):  
Basal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Basal Cell ◽  
Locally Advanced ◽  
Complete Response ◽  
Prolonged Treatment ◽  
Residual Tumour ◽  
8Th Edition

Background/AimsLocally advanced (T4 per American Joint Committee on Cancer (AJCC) 8th edition) periocular basal cell carcinoma (BCC) can lead to loss of the eye. We report the neoadjuvant use of vismodegib followed by surgery in patients with such lesions with eye preservation as primary goal.MethodsThis retrospective interventional study includes all patients with a T4 periocular BCC (per 8th edition AJCC for eyelid carcinoma) treated by the senior author between 2013 and 2017 with neoadjuvant vismodegib prior to definitive surgery.ResultsEight patients had a T4 tumour. Six patients presented with recurrent disease. Indications for neoadjuvant treatment were an unresectable tumour in one patient, an attempt to avoid an orbital exenteration in six patients and an attempt to avoid disfiguring facial surgery in one patient. Patients were treated for a median of 14 months (range: 4–36 months). All patients underwent an eye-sparing surgery following neoadjuvant vismodegib and all final surgical margins were negative for tumour. Five patients had a complete response to vismodegib with no microscopic residual BCC found during surgery; three patients had a significant partial response with residual tumour found on pathology. At last follow-up, a mean of 18 (range: 6–43) months after surgery, all patients were off-vismodegib and alive without evidence of disease.ConclusionsNeoadjuvant vismodegib for locally advanced (T4) periocular BCC enabled an eye-sparing surgery in all patients in our cohort. Prolonged treatment was well tolerated by most patients. Over half of patients achieved a complete response with no residual microscopic disease. Careful long-term follow-up is needed to confirm long-term disease-free survival.

Sign in / Sign up

Export Citation Format

Share Document